HG-12-6

Cat. No.: CAS No.: Molecular Formula: Molecular Weight: Target: Pathway: Storage:	HY-123956 2222354-57-4 C ₂₉ H ₂₇ F ₃ N ₆ O ₂ S 580.62 IRAK Immunology/Inflammation Please store the product under the recommended conditions in the Certificate of Analysis.	
---	--	--

BIOLOGICAL ACTIVITY			
BIOLOGICAL ACTIVITY			
Description	HG-12-6 is a type II inhibitor of IRAK4. HG-12-6 shows preferential binding to unphosphorylated inactive IRAK4 with an IC ₅₀ of 165 nM. HG-12-6 can modulate IRAK4 activity in autoimmunity and inflammation ^[1] .		
IC ₅₀ & Target	IRAK4IRAK4165 nM (IC50,2876 nM (IC50, Phosphorylated active IRAK4)Unphosphorylated		
In Vitro	The in-house compound HG-12-6 has a similar chemical scaffold as Ponatinib. The most differentiating components are the head of the inhibitor and the lack of a methyl substituent on ring A. Without the methyl substituent on ring A, the entire HG-12-6 molecule shifts inward to the ATP pocket in comparison with the binding mode of Ponatinib ^[1] . HG-12-6 has a better binding affinity for the unphosphorylated inactive IRAK4 kinase domain (IC ₅₀ of 165 nM) than the phosphorylated active IRAK4 kinase domain (IC ₅₀ of 2876 nM) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

REFERENCES

[1]. Wang L, et al. Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor-associated kinase 4 (IRAK4). J Biol Chem. 2019 Mar 22;294(12):4511-4519.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA



Product Data Sheet